235 related articles for article (PubMed ID: 38181797)
1. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy.
Wienke J; Visser LL; Kholosy WM; Keller KM; Barisa M; Poon E; Munnings-Tomes S; Himsworth C; Calton E; Rodriguez A; Bernardi R; van den Ham F; van Hooff SR; Matser YAH; Tas ML; Langenberg KPS; Lijnzaad P; Borst AL; Zappa E; Bergsma FJ; Strijker JGM; Verhoeven BM; Mei S; Kramdi A; Restuadi R; Sanchez-Bernabeu A; Cornel AM; Holstege FCP; Gray JC; Tytgat GAM; Scheijde-Vermeulen MA; Wijnen MHWA; Dierselhuis MP; Straathof K; Behjati S; Wu W; Heck AJR; Koster J; Nierkens S; Janoueix-Lerosey I; de Krijger RR; Baryawno N; Chesler L; Anderson J; Caron HN; Margaritis T; van Noesel MM; Molenaar JJ
Cancer Cell; 2024 Feb; 42(2):283-300.e8. PubMed ID: 38181797
[TBL] [Abstract][Full Text] [Related]
2. Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.
Siebert N; Zumpe M; Schwencke CH; Biskupski S; Troschke-Meurer S; Leopold J; Zikoridse A; Lode HN
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444427
[TBL] [Abstract][Full Text] [Related]
3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
4. PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma.
Song M; Huang Y; Hong Y; Liu J; Zhu J; Lu S; Wang J; Sun F; Huang J; Xu J; Tang Y; Xia JC; Zhang Y
Oncoimmunology; 2024; 13(1):2289738. PubMed ID: 38125723
[TBL] [Abstract][Full Text] [Related]
5. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.
Grapin M; Richard C; Limagne E; Boidot R; Morgand V; Bertaut A; Derangere V; Laurent PA; Thibaudin M; Fumet JD; Crehange G; Ghiringhelli F; Mirjolet C
J Immunother Cancer; 2019 Jun; 7(1):160. PubMed ID: 31238970
[TBL] [Abstract][Full Text] [Related]
6. Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.
Chu X; Tian W; Wang Z; Zhang J; Zhou R
Mol Cancer; 2023 Jun; 22(1):93. PubMed ID: 37291608
[TBL] [Abstract][Full Text] [Related]
7. Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer.
Boissière-Michot F; Chateau MC; Thézenas S; Guiu S; Bobrie A; Jacot W
Front Immunol; 2022; 13():1058424. PubMed ID: 36544779
[TBL] [Abstract][Full Text] [Related]
8. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade.
Ma L; Gai J; Qiao P; Li Y; Li X; Zhu M; Li G; Wan Y
Biochem Biophys Res Commun; 2020 Oct; 531(2):144-151. PubMed ID: 32782142
[TBL] [Abstract][Full Text] [Related]
9. LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade.
Yoo KJ; Johannes K; González LE; Patel A; Shuptrine CW; Opheim Z; Lenz K; Campbell K; Nguyen TA; Miriyala J; Smith C; McGuire A; Tsai YH; Rangwala F; de Silva S; Schreiber TH; Fromm G
J Immunol; 2022 Aug; 209(3):510-525. PubMed ID: 35817517
[TBL] [Abstract][Full Text] [Related]
10. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
Front Immunol; 2021; 12():637146. PubMed ID: 34025646
[TBL] [Abstract][Full Text] [Related]
11. TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
Liu Z; Zeng H; Jin K; Yu Y; You R; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
Br J Cancer; 2022 May; 126(9):1310-1317. PubMed ID: 35039625
[TBL] [Abstract][Full Text] [Related]
12. TIGIT, a novel immune checkpoint therapy for melanoma.
Tang W; Chen J; Ji T; Cong X
Cell Death Dis; 2023 Jul; 14(7):466. PubMed ID: 37495610
[TBL] [Abstract][Full Text] [Related]
13. Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives.
Farhangnia P; Akbarpour M; Yazdanifar M; Aref AR; Delbandi AA; Rezaei N
Expert Rev Clin Immunol; 2022 Dec; 18(12):1217-1237. PubMed ID: 36154551
[TBL] [Abstract][Full Text] [Related]
14. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
Ge Z; Peppelenbosch MP; Sprengers D; Kwekkeboom J
Front Immunol; 2021; 12():699895. PubMed ID: 34367161
[TBL] [Abstract][Full Text] [Related]
15. Targeting the "PVR-TIGIT axis" with immune checkpoint therapies.
Gorvel L; Olive D
F1000Res; 2020; 9():. PubMed ID: 32489646
[TBL] [Abstract][Full Text] [Related]
16. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
[TBL] [Abstract][Full Text] [Related]
17. The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology.
Wienke J; Dierselhuis MP; Tytgat GAM; Künkele A; Nierkens S; Molenaar JJ
Eur J Cancer; 2021 Feb; 144():123-150. PubMed ID: 33341446
[TBL] [Abstract][Full Text] [Related]
18. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
[TBL] [Abstract][Full Text] [Related]
19. TIGIT Blockade Reshapes the Tumor Microenvironment Based on the Single-cell RNA-Sequencing Analysis.
Lang Y; Huang H; Jiang H; Wu S; Chen Y; Xu B; Liu Y; Zhu D; Zheng X; Chen L; Jiang J
J Immunother; 2024 Jun; 47(5):172-181. PubMed ID: 38545758
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.
Melaiu O; Mina M; Chierici M; Boldrini R; Jurman G; Romania P; D'Alicandro V; Benedetti MC; Castellano A; Liu T; Furlanello C; Locatelli F; Fruci D
Clin Cancer Res; 2017 Aug; 23(15):4462-4472. PubMed ID: 28270499
[No Abstract] [Full Text] [Related]
[Next] [New Search]